Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NUVO closed enrollment early in its U.S. double-blind Phase II trial of alfimeprase to treat venous catheter occlusion.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury